Pramipexole Treats Anhedonia in Depression
Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 30, 2026
The discovery that Pramipexole can effectively treat anhedonia in treatment-resistant depression could significantly impact the pharmaceutical market by expanding the drug's indications and creating new treatment avenues. This could lead to increased sales for the manufacturers of Pramipexole and potentially stimulate further research into drug repurposing for mental health conditions.
Researchers at Lund University and Sweden — Skåne County in Sweden have found that pramipexole, a drug typically used for Parkinson s disease, can be an effective add-on therapy for anhedonia in patients with treatment-resistant depression. The randomized, double-blind, placebo-controlled clinical trial involved 82 participants and showed that pramipexole improved motivation and pleasure, with effects persisting over a six-month follow-up. Brain imaging and activity monitors supported the theory that the drug affects the dopamine system. This drug repurposing strategy offers a promising new treatment option for a debilitating symptom of depression that current antidepressants often fail to address.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard